Precipio, Inc.PRPOEarnings & Financial Report
Precipio, Inc. is a specialty diagnostic firm that develops and provides advanced oncology, genetic, and rare disease testing solutions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, with a core focus on enhancing diagnostic accuracy and improving patient health outcomes.
Revenue
$5.6M
Gross Profit
$2.4M
Operating Profit
$-824.0K
Net Profit
$74.0K
Gross Margin
43.2%
Operating Margin
-14.6%
Net Margin
1.3%
YoY Growth
24.9%
EPS
$0.05
Precipio, Inc. Q2 FY2025 Financial Summary
Precipio, Inc. reported revenue of $5.6M (up 24.9% YoY) for Q2 FY2025, with a net profit of $74.0K (up 106.1% YoY) (1.3% margin). Cost of goods sold was $3.2M, operating expenses totaled $3.3M.
Key Financial Metrics
| Total Revenue | $5.6M |
|---|---|
| Net Profit | $74.0K |
| Gross Margin | 43.2% |
| Operating Margin | -14.6% |
| Report Period | Q2 FY2025 |
Precipio, Inc. Annual Revenue by Year
Precipio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $24.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $24.2M |
| 2024 | $18.6M |
| 2023 | $15.4M |
| 2022 | $9.8M |
Precipio, Inc. Quarterly Revenue & Net Profit History
Precipio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.8M | +28.4% | $526.0K | 7.7% |
| Q3 FY2025 | $6.9M | +30.4% | $-79.0K | -1.1% |
| Q2 FY2025 | $5.6M | +24.9% | $74.0K | 1.3% |
| Q1 FY2025 | $4.9M | +41.2% | $-884.0K | -18.0% |
| Q4 FY2024 | $5.3M | +21.5% | $-365.0K | -6.9% |
| Q3 FY2024 | $5.3M | +15.6% | $-626.0K | -11.9% |
| Q2 FY2024 | $4.5M | +23.6% | $-1.2M | -27.1% |
| Q1 FY2024 | $3.5M | +22.9% | $-2.1M | -59.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $4.5M | $5.3M | $5.3M | $4.9M | $5.6M | $6.9M | $6.8M |
| YoY Growth | 22.9% | 23.6% | 15.6% | 21.5% | 41.2% | 24.9% | 30.4% | 28.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.6M | $17.3M | $17.0M | $17.0M | $17.8M | $18.8M | $21.2M | $21.3M |
| Liabilities | $3.9M | $5.2M | $5.0M | $4.9M | $6.1M | $6.5M | $7.4M | $6.8M |
| Equity | $12.8M | $12.1M | $11.9M | $12.1M | $11.7M | $12.3M | $13.7M | $14.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-667000 | $500000 | $41000 | $565000 | $-44000 | $353000 | $10000 | $366000 |